Anlon Healthcare Peer Comparison

NSE: AHCL | BSE: 544497

₹31.51

₹2.86 (9.98%)

As on 25-Sep-2026IST

Market cap

₹1,680 Cr

Revenue (TTM)

₹174 Cr

P/E Ratio

57.8

P/B Ratio

6.3

Div. Yield

0 %

Edit

	Anlon Healthcare	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	1,680	36,902	28,103	16,761	15,213
Revenue (₹ Cr)	174	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	29.06	1,018.97	497.77	603.02	270.18
Net Margin (%)	16.65	10.47	20.72	22.63	23.29
RoE (%)	13.70	21.30	28.49	19.61	14.45
Price to Earnings	57.82	36.49	56.46	27.79	55.25
Price-To-Book	6.28	7.05	13.90	4.81	7.34

Income Statement (₹ Cr)

	Anlon Healthcare	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	171.97	9,203.54	2,022.99	2,551.83	1,054.89
Total Income	172.22	9,335.01	2,053.15	2,612.24	1,107.25
Total Expenditure	124.45	7,457.80	1,448.49	1,754.55	686.95
EBITDA	47.52	1,745.74	574.50	797.28	367.94
Depreciation	1.52	415.05	91.74	75.36	74.46
EBIT	45.99	1,330.70	482.76	721.93	293.48
Interest	3.74	143.67	23.95	5.37	0.82
Other Income	0.26	131.47	30.17	60.41	52.36
Exceptional Items	--	-31.35	76.40	-25.66	-3.28
Profit before Tax	42.51	1,287.14	488.98	751.31	344.65
Provision for Tax	13.42	345.87	124.98	186.83	85.42
Profit after Tax	29.09	941.27	364.00	564.48	259.23

	Anlon Healthcare	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	230.23	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	24.57	26.64	--	--	-1.92
Non-Current Liabilities	11.61	584.19	345.47	142.73	47.58
Current Liabilities	107.57	3,912.24	710.20	682.24	169.08
Total Liabilities	373.97	9,514.48	2,930.14	4,157.10	2,231.79

	Anlon Healthcare	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	65.70	3,861.01	1,447.01	1,333.54	981.68
Current Assets	308.26	5,612.10	1,483.13	2,823.56	1,250.11
Total Assets	373.97	9,514.48	2,930.14	4,157.10	2,231.79
Total Debt*	43.65	1,204.08	196.61	0.00	0.00
Net Current Assets	200.69	1,699.86	772.93	2,141.33	1,081.03
Contingent Liabilities	0.25	258.92	13.18	4.82	3.76

	Anlon Healthcare	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	-79.44	943.55	346.68	565.41	266.88
Cash Flow from Investing Activities	-36.34	-1,193.06	-423.73	-570.15	-142.72
Cash from Financing Activities	118.69	343.43	20.98	-64.34	-112.88
Net Cash Inflow / Outflow	2.92	93.92	-56.08	-69.08	11.28

	Anlon Healthcare	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	21.98	25.25	27.50	24.61	18.04
ROE (%)	18.73	20.09	21.43	18.41	13.54
ROA (%)	10.48	10.70	14.25	14.27	12.15
EBIT Margin (%)	27.78	20.40	29.89	33.61	39.84
Net Margin (%)	16.89	10.08	17.73	21.61	23.41
Cash Profit Margin (%)	17.80	14.44	22.53	24.81	31.63

	Anlon Healthcare	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	42.96	16.56	36.98	6.91	-12.10
EBIT Growth (%)	47.55	21.77	75.89	19.60	-23.76
Net Profit Growth (%)	41.77	33.05	39.94	16.24	-30.25
EPS Growth (%)	4.20	35.59	39.94	16.05	-29.80
Book Value Growth (%)	186.28	11.36	22.95	18.43	11.27

	Anlon Healthcare	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	2.07	32.73	42.34	21.18	40.73
Price / Book Value	2.57	6.13	8.23	3.60	5.27
Dividend Yield (%)	0.00	0.23	0.28	0.51	0.74
EV/EBITDA	13.21	16.68	25.23	13.94	25.25
Market Cap (₹ Cr)	591.58	30,257.56	15,412.11	11,956.86	10,627.92

	Anlon Healthcare	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.19	0.24	0.10	0.00	0.00
Short term debt to equity ratio	0.16	0.16	--	--	0.00
Current Ratio	2.87	1.43	2.09	4.14	7.39
Quick Ratio	1.81	0.82	1.37	3.12	5.46
Interest Coverage	12.36	9.96	21.42	140.86	419.57

	Anlon Healthcare	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	60.29	27.84	26.76	42.05	43.63
Asset Turnover	0.62	1.07	0.79	0.65	0.49
Receivable days	189.62	88.68	77.32	144.58	169.86
Inventory Days	173.44	84.11	80.83	96.67	97.92
Payable days	107.37	176.65	125.94	135.45	159.68
Cash Conversion Cycle	255.69	-3.86	32.22	105.80	108.11

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.